modelJ05AX31

Diagram of J05AX31

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:Lenacapavir
ATC code:J05AX31
route:subcutaneous
compartments:2
dosage:927mg
volume of distribution:6.16L
clearance:0.173L/h
other parameters in model implementation

Lenacapavir is a first-in-class long-acting capsid inhibitor used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are heavily treatment-experienced. It works by inhibiting the HIV-1 capsid protein, thereby disrupting multiple steps of the viral life cycle. Lenacapavir is approved for use in the United States and European Union.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers, after subcutaneous administration.

References

  1. Jogiraju, V, et al., & Singh, R (2025). Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study. Lancet (London, England) 405(10485) 1147–1154. DOI:10.1016/S0140-6736(25)00405-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40086460

  2. Marzolini, C, et al., & Khoo, S (2025). Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir. Expert opinion on drug metabolism & toxicology 21(2) 161–172. DOI:10.1080/17425255.2024.2415295 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39411777

  3. Beran, C, et al., & Sahloff, EG (2024). A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 40(4) 194–201. DOI:10.1177/87551225241259894 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39157636

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)